Developer docs
API playgroundTry for free, no card

Search company profiles

Stoked Bio

Full company profile

uuid007vmof

Namestring
Stoked Bio
Legal namestring
Stoked Bio Inc.
Websiteurl
stokedbio.com
Company typeenum
Private
Founded yearint
2024
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHamilton, Canada
HQ citystring
Hamilton
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibiotic drug discovery, antimicrobial resistance therapeutics, AI-guided drug discovery, pre-clinical biotechnology, microbiome-sparing antibiotics
Industry4 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Pre-clinical Antimicrobial Drug Discovery
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Out-licensing of compound rights
TypeLicensing Royalties
Description

Stoked Bio has licensed rights to enterololin for Crohn's disease to Accure Therapeutics; future revenue is expected to derive from upfront payments, milestone payments, and royalties tied to development and commercialization progress.

bioworld.com
2Inbound license of enterololin from McMaster University
TypeLicensing Royalties
Description

Exclusive global license from McMaster University enables Stoked Bio to lead regulatory and commercialization efforts for enterololin across multiple indications, providing the foundational IP for all downstream revenue.

biospace.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Stoked Bio is a pre-clinical biotechnology company that discovers and develops novel medicines against drug-resistant infectious diseases using an AI-guided drug discovery platform. Its lead asset is enterololin, a novel antibiotic licensed from McMaster University that selectively targets Enterobacteriaceae WHO priority pathogens and is being developed for Crohn's disease, with broader pipeline applications in Parkinson's Disease and brain cancer. The company commercializes assets via out-licensing to pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduced mechanism-of-action mapping time from 18 months-2+ years to approximately 6 months using AI-guided discovery
+2 more records
Product overview1 text field

Stoked Bio operates a single integrated AI-guided drug discovery platform through which it discovers and develops novel medicines against drug-resistant diseases. The core platform powers the company's discovery pipeline, whose flagship product is enterololin, a novel antibiotic candidate licensed exclusively from McMaster University and being developed initially for Crohn's disease, with broader applications targeting infectious diseases, cancer, Parkinson's Disease, and other hard-to-treat conditions.

Product and service2 records
1Enterololin
CategoryLead drug candidate (antibiotic)
Description

Novel antibiotic compound exclusively licensed from McMaster University that selectively targets Enterobacteriaceae bacteria classified as WHO priority pathogens without disrupting the broader microbiome. Lead indication is Crohn's disease, with potential applications in infectious diseases, Parkinson's Disease, and brain cancer. Developed for out-licensing to pharmaceutical partners.

2Stoked Bio Pipeline (Infectious Disease and Oncology)
CategoryDrug development pipeline
Description

Broader pipeline of drug candidates targeting infectious diseases and cancer, advanced using the company's AI-guided discovery platform and progressing candidates toward late-stage proof-of-concept and partnering discussions. Includes enterololin for Crohn's disease and additional programs in Parkinson's Disease and brain cancer.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing Partner
Description

McMaster University is the origin institution from which Stoked Bio was spun out in 2024 and founded by McMaster researcher Jon Stokes. McMaster granted Stoked Bio an exclusive global license to develop enterololin, a compound identified in McMaster's laboratory and described in Nature Microbiology, supporting Crohn's disease and broader infectious-disease programs.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Accure Therapeutics has licensed rights to enterololin from Stoked Bio as a new treatment for Crohn's disease, associated with recent patent disclosures of MMP inhibitors (oligopeptide derivatives targeting MMP-2 and MMP-9 enzymes). This represents Stoked Bio's first significant out-licensing transaction.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

MIT CSAIL and McMaster University jointly identified the new antibiotic compound enterololin, using a generative AI model (DiffDock) to map its mechanism of action in about six months. The compound has been licensed to spinout company Stoked Bio for optimization, with clinical trials potentially beginning within the next few years.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Entasis Therapeutics is a clinical-stage biopharmaceutical company developing targeted antibacterial therapies for drug-resistant infections. Directly comparable to Stoked Bio's antimicrobial focus and addressing the same WHO priority pathogen problem space.

2Isomorphic Labs
TypeBroad incumbent
Description

Isomorphic Labs is Alphabet's drug discovery company applying DeepMind's AI to pharma R&D. Comparable as a platform-based AI drug discovery company, but operating as a well-capitalized broad incumbent rather than a focused pre-clinical spinout.

TypeDirect peer
Description

Insilico Medicine is a clinical-stage AI-driven drug discovery company using generative AI and deep learning to identify novel small molecules across multiple therapeutic areas, including infectious disease and oncology. It is the most direct comparable to Stoked Bio's generative-AI, platform-led approach to discovering new medicines, though at much greater scale and stage.

TypeDirect peer
Description

Recursion applies an AI/ML-enabled platform to discover and develop novel therapeutics across multiple disease areas. Comparable to Stoked Bio in the platform-first, AI-led discovery model, though Recursion operates at significantly larger scale and is publicly listed.

TypeDirect peer
Description

Accure Therapeutics is Stoked Bio's licensee for enterololin in Crohn's disease and a clinical-stage biotech developing therapies for CNS and inflammatory conditions. Directly comparable as the company advancing the same asset and a relevant commercial-track peer.

TypeDirect peer
Description

Acurx Pharmaceuticals is a clinical-stage biotech developing a new class of antibiotics targeting hard-to-treat infections including C. difficile. Comparable to Stoked Bio in addressing the antibiotic-resistance market and advancing differentiated small molecules against priority pathogens.

7Iambic Therapeutics
TypeDirect peer
Description

Iambic Therapeutics is an early-stage AI-driven drug discovery company combining generative AI models with physics-based simulation to design small-molecule therapeutics. It is highly comparable to Stoked Bio in stage, AI-platform approach, and small-molecule focus.

TypeDirect peer
Description

Absci is a generative AI drug creation company focused on designing novel therapeutics using a zero-shot generative AI model. Comparable to Stoked Bio in leveraging AI for novel drug design, with overlap in the platform-first, multi-indication thesis.

TypeDirect peer
Description

Cidara Therapeutics is a biotechnology company developing novel anti-infectives, including its proprietary Cloudbreak platform for targeted immunotherapies against infectious disease. Comparable in the antimicrobial/infectious-disease focus and platform-based discovery approach.

TypeDirect peer
Description

BioVersys is a Swiss clinical-stage biotech developing small-molecule therapeutics to combat antimicrobial resistance. Comparable to Stoked Bio in target product profile (novel antibiotics against drug-resistant bacteria) and pipeline diversification.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stoked Bio

Pre-clinical Antimicrobial Drug Discoverystokedbio.com

Stoked Bio firmographics

Firmographics
Name
Stoked Bio
Legal name
Stoked Bio Inc.
Website
https://stokedbio.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Stoked Bio industry classification

Industry
Product category
Pre-clinical Antimicrobial Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals

Keywords

  • Antibiotic drug discovery
  • Antimicrobial resistance therapeutics
  • AI-guided drug discovery
  • Pre-clinical biotechnology
  • Microbiome-sparing antibiotics

Where Stoked Bio is headquartered

Location

Headquarters

HQ city
Hamilton
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Stoked Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Out-licensing of compound rights: Stoked Bio has licensed rights to enterololin for Crohn's disease to Accure Therapeutics; future revenue is expected to derive from upfront payments, milestone payments, and royalties tied to development and commercialization progress.
  2. Inbound license of enterololin from McMaster University: Exclusive global license from McMaster University enables Stoked Bio to lead regulatory and commercialization efforts for enterololin across multiple indications, providing the foundational IP for all downstream revenue.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels3 records

Stoked Bio product offering

Product offering

Core offering

Stoked Bio is a pre-clinical biotechnology company that discovers and develops novel medicines against drug-resistant infectious diseases using an AI-guided drug discovery platform. Its lead asset is enterololin, a novel antibiotic licensed from McMaster University that selectively targets Enterobacteriaceae WHO priority pathogens and is being developed for Crohn's disease, with broader pipeline applications in Parkinson's Disease and brain cancer. The company commercializes assets via out-licensing to pharmaceutical partners.

Product overview

Stoked Bio operates a single integrated AI-guided drug discovery platform through which it discovers and develops novel medicines against drug-resistant diseases. The core platform powers the company's discovery pipeline, whose flagship product is enterololin, a novel antibiotic candidate licensed exclusively from McMaster University and being developed initially for Crohn's disease, with broader applications targeting infectious diseases, cancer, Parkinson's Disease, and other hard-to-treat conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Enterololin Novel antibiotic compound exclusively licensed from McMaster University that selectively targets Enterobacteriaceae bacteria classified as WHO priority pathogens without disrupting the broader microbiome. Lead indication is Crohn's disease, with potential applications in infectious diseases, Parkinson's Disease, and brain cancer. Developed for out-licensing to pharmaceutical partners.
  • Stoked Bio Pipeline (Infectious Disease and Oncology) Broader pipeline of drug candidates targeting infectious diseases and cancer, advanced using the company's AI-guided discovery platform and progressing candidates toward late-stage proof-of-concept and partnering discussions. Includes enterololin for Crohn's disease and additional programs in Parkinson's Disease and brain cancer.

Quantifiable outcome

  • Reduced mechanism-of-action mapping time from 18 months-2+ years to approximately 6 months using AI-guided discovery
  • +2 more outcomes

Companies that use Stoked Bio

Customer profile

Segments2 records

Ideal customer profiles1 record

Stoked Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature3 records

Stoked Bio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • McMaster UniversityflagshipOEM/ Whitelabel/ Licensing PartnerMcMaster University is the origin institution from which Stoked Bio was spun out in 2024 and founded by McMaster researcher Jon Stokes. McMaster granted Stoked Bio an exclusive global license to develop enterololin, a compound identified in McMaster's laboratory and described in Nature Microbiology, supporting Crohn's disease and broader infectious-disease programs.
  • Accure TherapeuticscoreOEM/ Whitelabel/ Licensing PartnerAccure Therapeutics has licensed rights to enterololin from Stoked Bio as a new treatment for Crohn's disease, associated with recent patent disclosures of MMP inhibitors (oligopeptide derivatives targeting MMP-2 and MMP-9 enzymes). This represents Stoked Bio's first significant out-licensing transaction.
  • MIT Computer Science and Artificial Intelligence Laboratory (CSAIL)coreStrategic or Co-development PartnerMIT CSAIL and McMaster University jointly identified the new antibiotic compound enterololin, using a generative AI model (DiffDock) to map its mechanism of action in about six months. The compound has been licensed to spinout company Stoked Bio for optimization, with clinical trials potentially beginning within the next few years.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Stoked Bio competitors and assessment

Company assessment

Direct peers

  • Entasis Therapeutics: Entasis Therapeutics is a clinical-stage biopharmaceutical company developing targeted antibacterial therapies for drug-resistant infections. Directly comparable to Stoked Bio's antimicrobial focus and addressing the same WHO priority pathogen problem space.
  • Insilico Medicine: Insilico Medicine is a clinical-stage AI-driven drug discovery company using generative AI and deep learning to identify novel small molecules across multiple therapeutic areas, including infectious disease and oncology. It is the most direct comparable to Stoked Bio's generative-AI, platform-led approach to discovering new medicines, though at much greater scale and stage.
  • Recursion Pharmaceuticals: Recursion applies an AI/ML-enabled platform to discover and develop novel therapeutics across multiple disease areas. Comparable to Stoked Bio in the platform-first, AI-led discovery model, though Recursion operates at significantly larger scale and is publicly listed.
  • Accure Therapeutics: Accure Therapeutics is Stoked Bio's licensee for enterololin in Crohn's disease and a clinical-stage biotech developing therapies for CNS and inflammatory conditions. Directly comparable as the company advancing the same asset and a relevant commercial-track peer.
  • Acurx Pharmaceuticals: Acurx Pharmaceuticals is a clinical-stage biotech developing a new class of antibiotics targeting hard-to-treat infections including C. difficile. Comparable to Stoked Bio in addressing the antibiotic-resistance market and advancing differentiated small molecules against priority pathogens.
  • Iambic Therapeutics: Iambic Therapeutics is an early-stage AI-driven drug discovery company combining generative AI models with physics-based simulation to design small-molecule therapeutics. It is highly comparable to Stoked Bio in stage, AI-platform approach, and small-molecule focus.
  • Absci: Absci is a generative AI drug creation company focused on designing novel therapeutics using a zero-shot generative AI model. Comparable to Stoked Bio in leveraging AI for novel drug design, with overlap in the platform-first, multi-indication thesis.
  • Cidara Therapeutics: Cidara Therapeutics is a biotechnology company developing novel anti-infectives, including its proprietary Cloudbreak platform for targeted immunotherapies against infectious disease. Comparable in the antimicrobial/infectious-disease focus and platform-based discovery approach.
  • BioVersys: BioVersys is a Swiss clinical-stage biotech developing small-molecule therapeutics to combat antimicrobial resistance. Comparable to Stoked Bio in target product profile (novel antibiotics against drug-resistant bacteria) and pipeline diversification.

Broad incumbents

  • Isomorphic Labs: Isomorphic Labs is Alphabet's drug discovery company applying DeepMind's AI to pharma R&D. Comparable as a platform-based AI drug discovery company, but operating as a well-capitalized broad incumbent rather than a focused pre-clinical spinout.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Stoked Bio social profiles

Digital presence

Stoked Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stoked Bio leadership team

Management profile

Number of profiles

Profiles3 records

Stoked Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stoked Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stoked Bio

What does Stoked Bio do?

Stoked Bio is a pre-clinical biotechnology company that discovers and develops novel medicines against drug-resistant infectious diseases using an AI-guided drug discovery platform. Its lead asset is enterololin, a novel antibiotic licensed from McMaster University that selectively targets Enterobacteriaceae WHO priority pathogens and is being developed for Crohn's disease, with broader pipeline applications in Parkinson's Disease and brain cancer. The company commercializes assets via out-licensing to pharmaceutical partners.

Is Stoked Bio a public or private company?

Stoked Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Stoked Bio founded?

Stoked Bio was founded in 2024. It employs 11 to 50 people.

Where is Stoked Bio based?

Stoked Bio is headquartered in Hamilton, Canada, in the North America region.

How does Stoked Bio make money?

Two revenue lines are on record. Out-licensing of compound rights are the primary driver. The others are inbound license of enterololin from McMaster University.

Who are Stoked Bio's main competitors?

Direct peers on record are Entasis Therapeutics, Insilico Medicine, Recursion Pharmaceuticals, Accure Therapeutics, Acurx Pharmaceuticals, Iambic Therapeutics, Absci, Cidara Therapeutics and BioVersys. Isomorphic Labs is listed as a broad incumbent.

Does Stoked Bio have an API?

No public API is recorded for Stoked Bio.

What industry is Stoked Bio in?

Stoked Bio's product category is Pre-clinical Antimicrobial Drug Discovery. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Daily NewsMcMaster spin-out biotech company gets $2.5M in seed funding to develop critical medicinesStoked Bio Inc., a biotechnology company spun out of McMaster University in Canada, has secured $2.5 million in seed funding to develop a pipeline of medicines targeting infectious diseases and cancer, with the round being oversubscribed indicating strong investor confidence. The company's lead drug candidate is enterololin, a novel antibiotic targeting Enterobacteriaceae bacteria classified as priority pathogens by the World Health Organization, with potential applications in treating Crohn's disease alongside other hard-to-treat conditions including Parkinson's Disease and brain cancer. The funding, combined with a $2 million grant from the Weston Family Foundation, will support advancing the company's drug candidates toward late-stage proof-of-concept and initiate partnering discussions.Daily NewsMcMaster spin-out company gets $2.5M in seed funding, supporting the development of critical new medicinesStoked Bio Inc., a Canadian biotechnology company spun out of McMaster University in 2024, has secured $2.5 million in early-stage seed funding to advance its pipeline of new medicines targeting infectious diseases and cancer. The company, founded by McMaster researcher Jon Stokes, leverages an AI-guided drug discovery platform and is developing a lead antibiotic candidate called enterololin against World Health Organization priority pathogens, with the funding round being oversubscribed indicating strong investor confidence.BioWorldFinancings for May 4, 2026On May 4, 2026, biopharma and med-tech companies including Cue, Oberland, Rein, Senseonics, Stoked Bio, and Techcyte raised funds through public or private financings. No specific amounts or deal terms were disclosed.BioSpaceStoked Bio Announces the Closing of Seed Financing RoundStoked Bio closed a $2.5 million seed financing round led by angel investors, with 99% from Ontario. The funds will advance its pipeline of anti-infectives and cancer therapeutics, including Enterololin, toward proof of concept. The company plans to initiate partnering discussions.GlobeNewswireStoked Bio Secures Exclusive Global License to Develop a Promising New Therapy for Crohn’s DiseaseStoked Bio has secured an exclusive global license from McMaster University to develop Enterololin, a compound identified in McMaster's laboratory and described in Nature Microbiology. The company aims to develop Enterololin as a treatment for Crohn’s disease, focusing on its unique mechanism to target specific bacteria without disrupting the microbiome.BioSpaceStoked Bio Licenses Global Rights for Novel Antibiotic from McMaster UniversityStoked Bio Inc. announced it has secured an exclusive global license from McMaster University for Enterololin, a novel narrow-spectrum antibiotic discovered in Dr. Jon Stokes' laboratory and published in Nature Microbiology. The compound selectively targets adherent-invasive E. coli implicated in Crohn's disease and uses a novel mechanism of action predicted using AI tools in collaboration with researchers at the Massachusetts Institute of Technology, potentially avoiding the broad microbiome disruption characteristic of existing antibiotics. Under the agreement, Stoked Bio obtains global patent rights and will lead further development, regulatory strategy, and commercialization, while McMaster retains an ongoing research collaboration.Daily NewsNew antibiotic targets IBD — and AI predicted how it would work before scientists could prove itResearchers at McMaster University and MIT have discovered enterololin, a narrow-spectrum antibiotic targeting inflammatory bowel diseases like Crohn's, which was verified in lab studies after AI software correctly predicted its mechanism of action in just 100 seconds. The AI-assisted approach reduced the typical mechanism-of-action study timeline from two years to six months and costs from approximately $2 million to $60,000. Stoked Bio, a spin-out company founded by the lead researcher, has licensed the drug and is optimizing it for human trials, which could begin within three years.MITAI maps how a new antibiotic targets gut bacteriaResearchers at MIT's Computer Science and Artificial Intelligence Laboratory (CSAIL) and McMaster University have identified a new antibiotic compound called enterololin using a generative AI model called DiffDock, which maps how molecules bind to bacterial proteins in months rather than the years traditionally required. The compound selectively suppresses Escherichia coli bacteria linked to Crohn's disease flare-ups while leaving the rest of the gut microbiome largely intact, outperforming the common antibiotic vancomycin in mouse models. The researchers' spinout company Stoked Bio has licensed enterololin and is optimizing it for human use, with clinical trials potentially beginning within a few years.